| Recruiting | Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults NCT06988618 | Galderma R&D | — |
| Active Not Recruiting | Efficacy of Topical Cannabidiol for Eczema NCT06994520 | Khon Kaen University | Phase 2 |
| Recruiting | Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis NCT06779136 | Shanghai Mabgeek Biotech.Co.Ltd | Phase 3 |
| Recruiting | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP NCT06516952 | Incyte Corporation | Phase 3 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP NCT06516965 | Incyte Corporation | Phase 3 |
| Recruiting | Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis NCT06554509 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 / Phase 3 |
| Active Not Recruiting | A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis NCT06527404 | Amgen | Phase 3 |
| Active Not Recruiting | Study on the Treatment of Prurigo Nodularis With Stapokibart Injection NCT06424470 | Keymed Biosciences Co.Ltd | Phase 3 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-A NCT06342713 | BeiGene | Phase 1 |
| Recruiting | A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of NCT06293053 | Sanofi | Phase 3 |
| Unknown | Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis NCT06201715 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Active Not Recruiting | A Study of Barzolvolimab in Patients With Prurigo Nodularis NCT06366750 | Celldex Therapeutics | Phase 2 |
| Recruiting | Upadacitinib for Prurigo Nodularis NCT06773403 | Psoriasis Treatment Center of Central New Jersey | Phase 4 |
| Completed | Effect of EMD Protocol for Urge on Dermatology-specific Quality of Life NCT06427122 | Tamar Nijsten | N/A |
| Completed | A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream NCT06213831 | Incyte Corporation | Phase 1 |
| Recruiting | A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes NCT06087627 | Sanofi | — |
| Active Not Recruiting | Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study NCT05991323 | Sanofi | — |
| Completed | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) NCT05764161 | Incyte Corporation | Phase 3 |
| Recruiting | Determinants of Chronic Inflammatory Skin Disease Trajectories NCT05928169 | University Hospital Schleswig-Holstein | — |
| Completed | A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Pru NCT05052983 | Galderma R&D | Phase 3 |
| Completed | A Study of CDX-0159 in Patients With Prurigo Nodularis NCT04944862 | Celldex Therapeutics | Phase 1 |
| Completed | A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis NCT05061693 | Incyte Corporation | Phase 2 |
| Completed | Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown NCT05038982 | Johns Hopkins University | Phase 2 |
| Recruiting | China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project NCT05316805 | Peking University First Hospital | — |
| Unknown | Transcriptomic Landscape of T Lymphocytes of Atopic Dermatitis, Atopic Prurigo Nodularis (of Besnier) and Non- NCT04681300 | Assistance Publique - Hôpitaux de Paris | — |
| Active Not Recruiting | A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) NCT04204616 | Galderma R&D | Phase 3 |
| Completed | Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) NCT04501666 | Galderma R&D | Phase 3 |
| Completed | A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) NCT04501679 | Galderma R&D | Phase 3 |
| Completed | Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodulari NCT03816891 | Genentech, Inc. | Phase 2 |
| Completed | Pain Outcomes Following Intralesional Corticosteroid Injections NCT03630198 | Vanderbilt University Medical Center | Phase 4 |
| Completed | Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurig NCT03677401 | Vyne Therapeutics Inc. | Phase 3 |
| Completed | PRISM Study-Pruritus Relief Through Itch Scratch Modulation NCT03497975 | Trevi Therapeutics | Phase 2 / Phase 3 |
| Completed | Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurig NCT03546816 | Vyne Therapeutics Inc. | Phase 3 |
| Terminated | Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) NCT03540160 | Vyne Therapeutics Inc. | Phase 3 |
| Completed | Safety and Efficacy of Nemolizumab in PN NCT03181503 | Galderma R&D | Phase 2 |
| Unknown | Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis NCT03576287 | Tanja Todberg, MD | Phase 1 / Phase 2 |
| Completed | Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis NCT02174432 | Trevi Therapeutics | Phase 2 / Phase 3 |
| Completed | Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis NCT02174419 | Trevi Therapeutics | Phase 2 / Phase 3 |
| Completed | A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodula NCT02196324 | Vyne Therapeutics Inc. | Phase 2 |
| Completed | Safety and Efficacy of CC-10004 for Prurigo Nodularis NCT00869089 | University Hospitals Cleveland Medical Center | Phase 2 |
| Completed | Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease NCT00507832 | University Hospital Muenster | Phase 2 |
| Unknown | Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis NCT00532519 | Hadassah Medical Organization | N/A |